Organization
Madrid, Spain
29 abstracts
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),
Abstract
Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).Org: Memorial Sloan Kettering Cancer Center, Carolina Urologic Research Center and GenesisCare US, British Columbia Cancer Agency (BCCA), Veterans Prostate Cancer Awareness, Novartis Pharmaceuticals Corporation,
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.Org: Centre Hospitalier De L Ardenne, Libramont-Chevigny, Belgium, Hospital Universitario Arnau de Vilanova; GEICAM Spanish Breast Cancer Group, Lleida, Spain, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, The Oncology Institute, Whittier, CA,
Abstract
Meta-analysis of perioperative immune checkpoint inhibitors in urothelial and renal cell carcinoma: Data from the latest available evidence.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Madrid, Spain, Medical Oncology Service, 12 de Octubre University Hospital,
Abstract
Usage pattern of anticoagulants in oncology patients receiving active anticancer therapies in Europe and Asia.Org: IQVIA, Amsterdam, Netherlands, London Regional Cancer Center, Madrid, Spain, Spain, Chicago, IL,
Abstract
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Org: Erasmus MC Cancer Center, Rotterdam, Netherlands Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Fondazione IRCCS Istituto Neurologico Carlo Besta,
Abstract
A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM).Org: Mayo Clinic, Rochester Regional Health System, MN, Jacksonville, Flare Therapeutics,
Abstract
Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain, University of California San Francisco,
Abstract
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.Org: Medical Oncology Group, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Ramón y Cajal University Hospital, Madrid, Spain, Cardiology Department, Biochemistry Department,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).Org: Yonsei University College of Medicine, Seoul, Korea, Republic of (South), Taipei Medical University Hospital, Taipei City, Taiwan, City of Hope Comprehensive Cancer Center,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
A prospective, non-interventional study among patients diagnosed with locally advanced or metastatic non–small-cell lung cancer to assess the adherence to oral antineoplastic therapy from data collected through patient-reported questionnaires and tablets count in Spain: LOADH study.Org: Hospital Universitario Arnau de Vilanova, Lleida, Spain, Spain, Medicine Department, Santiago de Compostela University,
Abstract
Intervening factors for participation and non-participation in colorectal cancer screening in Spain.Org: Spanish Association Against Cancer AECC, Madrid, Spain, Spain,
Abstract
A HEALTH CARE PROGRAM TO REDUCE RECENT DISABILITY DUE TO MUSCULOSKELETAL DISORDERS IN ELDERS: A PRELIMINARY ANALYSISOrg: Rheumatology, Hospital Clínico San Carlos, Spanish Foundation of Rheumatology, Primary Care Physicians, Health District 7,
Abstract
ANTINUCLEAR ANTIBODIES (ANA) IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMABOrg: Rheumatology unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, Inmunology Unit, La Paz University Hospital, Madrid, Spain, Spain,
Abstract
Are we treating with biological therapies women patients with real non-radiographic axial spondyloarthritis?Org: Hospital Provincial de Rosario, Rosario University, Argentina University Hospital La Paz, IdiPAZ Biobank, Madrid, Spain,
Abstract
AUTOANTIBODY PROFILE IN SYSTEMIC SCLEROSIS: CLINICAL SIGNIFICANCEOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, 12 OCTUBRE HOSPITAL, Immunology, UKM, Muenster, Germany, Madrid, Spain, Spain,
Abstract
A 7-YEARS EXPERIENCE OF PERCUTANEOUS VERTEBROPLASTY FOR OSTEOPOROTIC VERTEBRAL FRACTURES: ANALYSIS OF FACTORS DETERMINING OUTCOME IN 212 PATIENTSOrg: Orthopaedics, Neuroradiology, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Fundación Jiménez Díaz, Madrid, Spain,
Abstract
AXIAL MANIFESTATIONS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: ARE THEY SIMILAR?Org: Hospital La Paz, IdiPAZ Biobank, Rheumatology unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, Madrid, Spain, Spain,
Abstract
ACCURACY OF PHYSICAL EXAMINATION IN THE EVALUATION OF ROTATOR CUFF LESIONS DIAGNOSED BY MRIOrg: Rheumatology Department, Imaging Department, Biostatistics Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain,
Abstract
ASSOCIATION ANALYSIS OF MATRILIN-1 GENE GENOTYPES AND OSTEOARTHRITISOrg: Rheumatology Department, Gregorio Marañon General University Hospital, Madrid, Spain, Centro Reumatológico Strusberg, Department of Biochemistry and Molecular Biology, School of Medicine. National University of Córdoba, Molecular Genetics Unit,
Abstract
ANALYSIS OF NSAIDS USE IN PATIENTS REFERRED TO A RHEUMATOLOGY CONSULTATION: BENEFITS OF AN INTERNAL AUDITOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Nephrology, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain, Ramón y Cajal University Hospital, Madrid, Spain, Spain,
Abstract
ADALIMUMAB (HUMIRA®) IS EFFECTIVE AND SAFE IN TREATING RHEUMATOID ARTHRITIS (RA) IN REAL-LIFE CLINICAL PRACTICE: FINAL SUMMARY OF THE 6610 PATIENTS IN THE REACT STUDYOrg: Charité University Medicine Berlin, Humboldt University of Berlin, Berlin Heals, Germany, Gregorio Marañón University General Hospital,
Abstract
AUTOANTIBODIES DETECTION IN AN EARLY ARTHRITIS CLINIC: DIAGNOSTIC VALUE FOR RHEUMATOID ARTHRITIS?Org: Unit of Rheumatology, University of Padova, Department of Medicine, Padova, Italy, Hospital Santa Maria, Lisboa, Portugal, Service of Rheumatology,
Abstract
ASSESSING UTILITY VALUES IN RHEUMATOID ARTHRITIS PATIENTS: A COMPARISON BETWEEN THE TIME TRADE OFF AND THE EUROQOLOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Hospital Universitario Virgen Macarena, Sevilla, Spain, Investigation Unit, Sociedad Española de Reumatología, Madrid, Spain,